𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A phase III trial on the therapy of advanced pancreatic carcinoma evaluations of the mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin

✍ Scribed by Stephen Cullinan; Charles G. Moertel; Harry S. Wieand; Allan J. Schutt; James E. Krook; John F. Foley; Brian D. Norris; Carl G. Kardinal; Loren K. Tschetter; John F. Barlow

Publisher
John Wiley and Sons
Year
1990
Tongue
English
Weight
475 KB
Volume
65
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A prospective, randomized phase III tria
A prospective, randomized phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma
✍ Cesar Blajman; L. Balbiani; J. Block; F. Coppola; R. Chacon; L. Fein; S. Bonicat πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 105 KB πŸ‘ 1 views

## Background: A prospective, multicenter, randomized, phase iii trial comparing the efficacy of combination chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide (fac) with a combination of vinorelbine and doxorubicin (na) in the treatment of patients with advanced breast carcinoma w

A randomized Phase III trial of etoposid
A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma
✍ Fikri Δ°Γ§li; Δ°smail Γ‡elik; Faruk Aykan; AytuΗ§ Üner; Ahmet Demirkazik; Ahmet Γ–zet; πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 85 KB πŸ‘ 2 views

## BACKGROUND. Gastric carcinoma is a substantial health problem in Turkey, and the majority of patients present with inoperable disease. The aim of this randomized trial was to assess the activity of 5-fluorouracil versus etoposide when combined with epirubicin plus cisplatin in patients with adv

Combined cisplatin, doxorubicin, and mit
Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma : A Phase II FONICAP trial
✍ Maria Cristina Pennucci; Andrea Ardizzoni; Paolo Pronzato; Marina Fioretti; Clau πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 182 KB πŸ‘ 2 views

and cisplatin (P) yielded an objective response rate of 25% and a subjective response rate of 50% in patients with mesothelioma. In human mesothelioma cell

A phase II trial of methotrexate, cispla
A phase II trial of methotrexate, cisplatin, 5-fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma
✍ William K. Oh; Judith Manola; Jerome P. Richie; Kevin R. Loughlin; Philip W. Kan πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 78 KB πŸ‘ 2 views

The current treatment of advanced urothelial carcinoma generates high response rates but is associated with poor overall survival. The current study evaluated the efficacy and toxicity of a new combination of active drugs in the treatment of urothelial carcinoma. ## METHODS. Twenty-four patients

The combination of cisplatin, doxorubici
The combination of cisplatin, doxorubicin, and mitomycin (PAM) compared with the FAM regimen in treating advanced gastric carcinoma: A phase II randomized trial of the Italian oncology group for clinical research
✍ Vincenzo De Lisi; Giorgio Cocconi; Francesco Angelini; Francesco Cavicchi; Franc πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 482 KB πŸ‘ 2 views

## BACKGROUND. In a randomized Phase I1 study, the authors evaluated the activity and toxicity of the new cisplatin, doxorubicin, and mitomycin C (PAM) comhination, that includes cisplatin (P) instead of 5-fluorouracil as in the 5-fluorouracil, doxorubicin, and mitomycin C (FAM) Combination, in pat